The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.
Matei Gaginsky
International
Foto: Sylvain ROBIN / Alamy / Profimedia
Always see our news on Google
The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.
Sources
Latest News
13:21
Meteoplus: The drought in Central Europe keeps the Danube at critical levels, despite the abundant rainfall in Romania
12:57
Latvia has closed its border with Belarus citing technical reasons amid an increase in illegal crossings.
12:32
New online fraud campaign: criminals present themselves as the Romanian Police and send SMS messages with alleged traffic fines and short payment deadlines.
11:30
South Korea records a historic high of 42.5°C in Yangsan, the highest temperature since 1904
11:11
The resources of the U.S. Navy are insufficient for the defense of Israel, warns the highest American military official in Europe.
See more news
NEWS ON THE SAME TOPICS
Current Affairs
The Competition Council has fined five companies 6.42 million lei for limiting the sales of medical imaging equipment in Romania.
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
